文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

重症COVID-19患者接受体外膜氧合支持时的出血与血栓事件:一项全国性队列研究

Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study.
PubMed 文献 · Intensive Care Med · 2022-07-13
一句话结论ECMOSARS登记显示,重症COVID-19 ECMO患者出血发生率高且与院内死亡独立相关(adjOR=2.91),颅内出血风险最高(adjOR=13.5),血栓事件与死亡无显著关联。

该研究基于法国ECMOSARS登记,纳入截至2022年3月31日接受ECMO支持的620例重症COVID-19患者,分析出血与血栓事件及其危险因素。结果:29%仅出血、16%仅血栓、20%合并出血与血栓;院内死亡率55.7%。出血事件与院内死亡独立相关(adjOR=2.91[1.94-4.4]),血栓事件无关(adjOR=1.02[0.68-1.53]);颅内出血关联最强(adjOR=13.5[4.4-41.5])。ECMO前通气≥7天和ECMO支持时长与出血相关;纤维蛋白原≥6 g/L和ECMO支持时长与血栓相关。

要点

  • 620例重症COVID-19 ECMO患者中,29%仅出血、16%仅血栓、20%合并出血与血栓,院内死亡率55.7%。
  • 出血事件与院内死亡独立相关(adjOR=2.91[1.94-4.4]),颅内出血关联最强(adjOR=13.5[4.4-41.5])。
  • 血栓事件与院内死亡无显著关联(adjOR=1.02[0.68-1.53])。
  • ECMO前通气时长≥7天和ECMO支持时长与出血相关;纤维蛋白原≥6 g/L和ECMO支持时长与血栓相关。
  • 出血最常见部位为置管部位(18%)、耳鼻喉(12%)、肺出血(9%)和颅内出血(8%)。

适用人群与场景

  • 法国ECMOSARS登记中截至2022年3月31日接受ECMO支持的重症COVID-19患者,且出血与血栓事件数据完整。

红旗征与不能漏的情况

  • 颅内出血发生率为8%,与院内死亡关联最强(adjOR=13.5[4.4-41.5])。
  • 出血事件与院内死亡独立相关(adjOR=2.91[1.94-4.4])。

研究设计与关键结果

  • 研究类型:基于法国ECMOSARS登记的全国性队列研究;样本量620例;人群:重症COVID-19接受ECMO支持且出血与血栓事件数据完整的患者。
  • 出血与血栓事件分布:29%仅出血,16%仅血栓,20%合并出血与血栓。
  • 出血类型:置管部位18%、耳鼻喉12%、肺出血9%、颅内出血8%。
  • 血栓事件以设备相关血栓和肺栓塞/肺血栓形成为主。
  • 院内死亡率55.7%。
  • 出血事件与院内死亡相关(adjOR=2.91[1.94-4.4]),血栓事件与院内死亡无显著关联(adjOR=1.02[0.68-1.53])。
  • 颅内出血与院内死亡强关联(adjOR=13.5[4.4-41.5])。
  • ECMO前通气时长≥7天和ECMO支持时长与出血相关;纤维蛋白原≥6 g/L和ECMO支持时长与血栓相关。

证据类型、等级与局限

  • 证据类型:全国性队列研究(ECMOSARS登记)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ECMO支持时长与出血和血栓风险均升高相关,支持制定策略以缩短ECMO支持时间。
  • 颅内出血发生率高于非COVID患者报告值,且携带最高死亡风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To describe bleeding and thrombotic events and their risk factors in patients receiving extracorporeal membrane oxygenation (ECMO) for severe coronavirus disease 2019 (COVID-19) and to evaluate their impact on in-hospital mortality.

METHODS: The ECMOSARS registry included COVID-19 patients supported by ECMO in France. We analyzed all patients included up to March 31, 2022 without missing data regarding bleeding and thrombotic events. The association of bleeding and thrombotic events with in-hospital mortality and pre-ECMO variables was assessed using multivariable logistic regression models.

RESULTS: Among 620 patients supported by ECMO, 29% had only bleeding events, 16% only thrombotic events and 20% both bleeding and thrombosis. Cannulation site (18% of patients), ear nose and throat (12%), pulmonary bleeding (9%) and intracranial hemorrhage (8%) were the most frequent bleeding types. Device-related thrombosis and pulmonary embolism/thrombosis accounted for most of thrombotic events. In-hospital mortality was 55.7%. Bleeding events were associated with in-hospital mortality (adjusted odds ratio (adjOR) = 2.91[1.94-4.4]) but not thrombotic events (adjOR = 1.02[0.68-1.53]). Intracranial hemorrhage was strongly associated with in-hospital mortality (adjOR = 13.5[4.4-41.5]). Ventilation duration before ECMO ≥ 7 days and length of ECMO support were associated with bleeding. Thrombosis-associated factors were fibrinogen ≥ 6 g/L and length of ECMO support.

CONCLUSIONS: In a nationwide cohort of COVID-19 patients supported by ECMO, bleeding incidence was high and associated with mortality. Intracranial hemorrhage incidence was higher than reported for non-COVID patients and carried the highest risk of death. Thrombotic events were less frequent and not associated with mortality. Length of ECMO support was associated with a higher risk of both bleeding and thrombosis, supporting the development of strategies to minimize ECMO duration.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mansour A, Flecher E, Schmidt M, et al. Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. Intensive Care Med. 2022. PMID: 35829723. doi:10.1007/s00134-022-06794-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。